ONCOLOGY

Findings from a large multinational trial of 9.7K patients.

Risk rises with smoking intensity and duration.

Favorable phase 2 findings validate Nectin-4 as a therapeutic target.

Oncologic outcomes were similar to that of moderate hypofractionation.

Study shows benefit in patients with positive margins or extracapsular extension.

Phase 3 ARAMIS showed significant improvement in metastasis-free survival.

Large cohort study compares immunotherapy and carboplatin-based chemotherapy.

Robotic-assisted surgery may attenuate risk in patients with CKD.

Findings led to accelerated FDA approval.

NICE recommends special arrangements for clinical use

Phase 3 ARCHES trial reports 61% reduction in risk for progression or death.

Large multicenter retrospective analysis compares ENRT and SBRT.

The proposed recommendations are based on a review of existing guidance and published literature.

ICU-level complications, nonhome discharge.